News
OBI Pharma, Inc. to Present at the J.P. Morgan Healthcare Conference
SAN FRANCISCO, Jan. 9, 2020 — OBI Pharma, Inc., a Taiwan biopharma company (TPEx: 4174), announced that Michael Chang, Ph.D. Chairman and CEO, will present a company overview at the 38th Annual …
OBI Pharma Granted FDA Orphan Drug Designation for the Treatment of Pancreatic Cancer for Its Antibody-Drug Conjugate (ADC) Targeted Cancer Therapy, OBI-999
First Orphan Drug Designation for OBI-999, a novel first-in-class Antibody-Drug Conjugate targeting Globo H, a glycolipid antigen found on multiple tumor types TAIPEI, Taiwan, Dec. 26, …
OBI Pharma Announces Initiation of a Phase 1/2 Study of Its Antibody-Drug Conjugate (ADC) Targeted Cancer Therapy, OBI-999.
TAIPEI, Taiwan, December 18, 2019 ─ OBI Pharma, a Taiwan biopharma company (TPEx: 4174), today announced the initiation of a Phase 1/2 clinical trial (ClinicalTrials.gov …
OBI Pharma Announces U.S. FDA Clearance of IND Application for a Phase 1/2 Study of its Antibody-Drug Conjugate (ADC) targeted cancer therapy, OBI-999
First Clinical Trial to test the Safety and Efficacy of based on an ADC (Antibody Drug Conjugate) targeting Globo H, a glycolipid antigen found on …
OBI Pharma Announces Poster Presentations at AACR 2019 for Novel Globo H Immuno-Oncology Therapeutics: OBI-888 and OBI-999
Poster Presentations to highlight on mechanism of action, anti-tumor efficacy and pharmacokinetics profile for OBI-888 (Globo H mAb) and OBI-999 (Globo H ADC) TAIPEI, Taiwan, …